Literature DB >> 28110858

The prevalence of diagnosed and undiagnosed hepatitis C virus infection in Navarra, Spain, 2014-2016.

Aitziber Aguinaga1, Jorge Díaz-González2, Alejandra Pérez-García3, Laura Barrado4, Iván Martínez-Baz5, Itziar Casado5, Regina Juanbeltz5, Carmen Ezpeleta1, Jesús Castilla6.   

Abstract

OBJECTIVE: To estimate the prevalence of hepatitis C virus (HCV) infection in Navarra, Spain, as well as to distinguish between diagnosed and undiagnosed infections.
METHODS: A study was conducted on patients scheduled for surgery unrelated to HCV infection. They were all tested for HCV antibodies, under a routine scheme, from January 2014 to September 2016. Patients with a positive result by enzyme immunoassay were confirmed using immunoblot and/or HCV-RNA. Previous laboratory results were also taken into account. The prevalence was adjusted to the sex and age structure of the Navarra population.
RESULTS: The study included a total of 7,378 patients with a median age 46 years, of whom 50% women. HCV antibodies were detected in 69 patients, which is a prevalence in the population of 0.83% (95% confidence interval: 0.64-1.05), and was higher in men (1.11%) than in women (0.56%; P=.0102). Among the HCV positive patients, 67 (97%) had had another previous positive result. Population prevalence of previous positive HCV was 0.80%, and was 0.03% for a new diagnosis. Of the HCV positive patients, 78% had detectable HCV-RNA. It was estimated that 0.65% of the population had had detectable HCV-RNA, and 0.51% continued to have it when recruited into the study.
CONCLUSION: Previous estimates of prevalence of HCV infection should be revised downwards. Only a small proportion of HCV positive patients remain undiagnosed, and only a small part have active infection.
Copyright © 2016 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Entities:  

Keywords:  Carga viral; Encuesta seroepidemiológica; Epidemiology; Epidemiología; España; Hepatitis C virus; Seroepidemiological survey; Seroprevalence; Seroprevalencia; Spain; Viral load; Virus de la hepatitis C

Mesh:

Substances:

Year:  2017        PMID: 28110858     DOI: 10.1016/j.eimc.2016.12.008

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin (Engl Ed)        ISSN: 2529-993X


  4 in total

1.  Cost-effectiveness analysis of chronic hepatitis C treatment in the prison population in Spain.

Authors:  A Marco; R Domínguez-Hernández; M A Casado
Journal:  Rev Esp Sanid Penit       Date:  2020-07-20

2.  Seroprevalence and epidemiology of hepatitis B and C viruses in pregnant women in Spain. Risk factors for vertical transmission.

Authors:  Ángeles Ruiz-Extremera; María Del Mar Díaz-Alcázar; José Antonio Muñoz-Gámez; Marta Cabrera-Lafuente; Estefanía Martín; Rosa Patricia Arias-Llorente; Pilar Carretero; José Luis Gallo-Vallejo; Francisca Romero-Narbona; M A Salmerón-Ruiz; Clara Alonso-Diaz; Rafael Maese-Heredia; Lucas Cerrillos; Ana María Fernández-Alonso; Carmen Camarena; Josefa Aguayo; Miguel Sánchez-Forte; Manuel Rodríguez-Maresca; Alfredo Pérez-Rivilla; Rosa Quiles-Pérez; Paloma Muñoz de Rueda; Manuela Expósito-Ruiz; Federico García; Fernando García; Javier Salmerón
Journal:  PLoS One       Date:  2020-05-21       Impact factor: 3.240

3.  Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain.

Authors:  Regina Juanbeltz; Alejandra Pérez-García; Aitziber Aguinaga; Iván Martínez-Baz; Itziar Casado; Cristina Burgui; Silvia Goñi-Esarte; Jesús Repáraz; José Manuel Zozaya; Ramón San Miguel; Carmen Ezpeleta; Jesús Castilla
Journal:  PLoS One       Date:  2018-12-04       Impact factor: 3.240

4.  A population-based screening for hepatitis C antibodies and active infection using a point-of-care test in a low prevalence area.

Authors:  Ângela Carvalho-Gomes; Almudena Cubells; Carmina Pallarés; Vanessa Hontangas; Isabel Conde; Tomasso Di Maira; Salvador Peiró; Gabriel Sanfélix-Gimeno; F Xavier López-Labrador; Marina Berenguer
Journal:  PLoS One       Date:  2020-02-11       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.